Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA

EQS-News: Eckert & Ziegler SE / Key word(s): Conference/Miscellaneous
Eckert & Ziegler Hosts Second Radionuclide Theranostics Forum in Boston, MA

31.05.2024 / 09:00 CET/CEST
The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

BOSTON, Mass., May 31, 2024 - Eckert & Ziegler reports about the successful
completion of the 2nd annual Boston Radionuclide Theranostics Forum,
reaffirming its pivotal role in the field of radiopharmaceuticals. Building
on the momentum of last year's inaugural event, the Forum once again brought
together leading experts, potential and existing partners, and key industry
players to delve into the pressing topics and innovations driving the
rapidly evolving radiotheranostics market.

The Forum, held on May 30, 2024, explored solutions to challenges in
healthcare system readiness, isotope production as well as development of
radiopharmaceuticals and successful deals in the radiotherapeutic space.
This year's event saw an even larger turnout, reflecting the growing
interest and importance of this annual gathering.

"Numerous announcements prove that the radiopharmaceutical market is more
dynamic and vibrant than ever before. We were honored to host the second
Radionuclide Theranostics Forum in Boston in such exciting times," said Dr.
Harald Hasselmann, CEO of Eckert & Ziegler SE. "This year's discussions
focused on these new developments, while building on the foundations of
2023. Always having in mind future market challenges, the ideas, and
partnerships that emerged here will advance precision oncology worldwide in
the long term."

Initiated and sponsored by Eckert & Ziegler, the Boston Radionuclide
Theranostics Forum has quickly become a fixture in the nuclear medicine
calendar. The half-day event featured talks by over a dozen international
experts and executives from clinical, industry, and research backgrounds.
Attendees engaged in dynamic panel discussions, further solidifying the
Forum's reputation as a critical platform for knowledge exchange and
innovation in radiotheranostics.

Attendance was by invitation only, and the event once again reached full
capacity. The 3rd edition of the Forum will be held on May 29, 2025. As it
continues to grow and evolve, Eckert & Ziegler is committed to fostering a
collaborative environment that advances the science and application of
radiotheranostics, ultimately improving patient outcomes worldwide.

About Eckert & Ziegler.
Eckert & Ziegler SE with more than 1,000 employees is a leading specialist
for isotope-related components in nuclear medicine and radiation therapy.
The company offers a broad range of services and products for the
radiopharmaceutical industry, from early development work to contract
manufacturing and distribution. Eckert & Ziegler shares (ISIN DE0005659700)
are listed in the TecDAX index of Deutsche Börse.
Contributing to saving lives.

Contact
Eckert & Ziegler SE
Robert-Rössle-Str. 10, 13125 Berlin, Germany
Karolin Riehle, Investor Relations / Jan Schöpflin, Marketing
karolin.riehle@ezag.de / jan.schoepflin@ezag.de
Tel.: +49 (0) 30 / 94 10 84-138; www.ezag.com


---------------------------------------------------------------------------

31.05.2024 CET/CEST Dissemination of a Corporate News, transmitted by EQS
News - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.

The EQS Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.eqs-news.com

---------------------------------------------------------------------------

   Language:       English
   Company:        Eckert & Ziegler SE
                   Robert-Rössle-Str.10
                   13125 Berlin
                   Germany
   Phone:          +49 30 941084-138
   Fax:            +49 30 941084-0
   Internet:       www.ezag.de
   ISIN:           DE0005659700
   WKN:            565970
   Indices:        SDAX, TecDax,
   Listed:         Regulated Market in Frankfurt (Prime Standard);
                   Regulated Unofficial Market in Berlin, Dusseldorf,
                   Hamburg, Munich, Stuttgart, Tradegate Exchange
   EQS News ID:    1914763

End of News EQS News Service
---------------------------------------------------------------------------

1914763 31.05.2024 CET/CEST